Abstract:IGF2BP3 increased CTCF expression to promote the transcriptional process of NT5DC2, thus accelerating M2 macrophage polarization, which in turn increased cell proliferation, tube formation, and glucose metabolism and inhibited cell apoptosis, ultimately promoting the malignant progression of LUSC. Background Lung squamous cell carcinoma (LUSC) is a type of lung cancer that develops in the squamous cells. It is known to be promoted by the activation of various signaling pathways and the dysregulation of key regulatory molecules. One such molecule, 5′‐nucleotidase domain containing 2 (NT5DC2), has been identified as a critical regulator in various cancers including lung cancer. However, there are no data regarding its role in LUSC. Methods The mRNA expression of insulin‐like growth factor 2 mRNA–binding protein 3 (IGF2BP3), CCCTC‐binding factor (CTCF), and NT5DC2 was analyzed using quantitative real‐time polymerase chain reaction (qRT‐PCR), whereas their protein expression was assessed using a western blotting assay. Cell proliferation was determined using a cell counting kit‐8 (CCK‐8) assay. Cell apoptosis, CD11b expression, and CD206 expression were analyzed using flow cytometry. Tube formation was assessed through a tube formation assay. Glucose consumption, lactate production, and ATP levels were measured using colorimetric methods. The effect of NT5DC2 on the malignant progression of LUSC cells was analyzed using a xenograft mouse model assay. The levels of transforming growth factor‐beta 1 (TGF‐β1) and interleukin‐10 (IL‐10) were detected using enzyme‐linked immunosorbent assays. The associations among IGF2BP3, CTCF and NT5DC2 were identified using dual‐luciferase reporter assay, RNA immunoprecipitation assay and m6A RNA immunoprecipitation assay. Results The expression of NT5DC2 was found to be upregulated in LUSC tissues and cells when compared with normal lung tissues and normal human bronchial epithelial cells. Silencing of NT5DC2 inhibited LUSC cell proliferation, tube formation, glycolysis, M2 macrophage polarization, and tumor formation while inducing cell apoptosis. In addition, CTCF was found to transcriptionally activate NT5DC2 in LUSC cells. IGF2BP3 stabilized the mRNA expression of CTCF through m6A methylation. Further, overexpression of CTCF or NT5DC2 attenuated the effects of IGF2BP3 silencing in both NCI‐520 and SK‐MES‐1 cells. Conclusion The IGF2BP3/CTCF axis–dependent NT5DC2 promotes M2 macrophage polarization, thereby enhancing the malignant progression of LUSC. This study was the first to reveal the role of NT5DC2 in LUSC and the underlying mechanism. The result suggests that targeting the IGF2BP3/CTCF/NT5DC2 axis may have clinical significance in the treatment of LUSC.

NT5DC2 suppression restrains progression towards metastasis of non-small-cell lung cancer through regulation p53 signaling

NT5DC2 promotes tumor cell proliferation by stabilizing EGFR in hepatocellular carcinoma

Silencing oncogene cell division cycle associated 5 induces apoptosis and G1 phase arrest of non‐small cell lung cancer cells via p53‐p21 signaling pathway

PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway

CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1

NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer

Targeting DNAJC19 overcomes tumor growth and lung metastasis in NSCLC by regulating PI3K/AKT signaling

CTB-193M12.5 Promotes Hepatocellular Carcinoma Progression Via Enhancing NSD1-Mediated WNT10B/Wnt/β-Catenin Signaling Activation

Decreased RNA‑binding protein IGF2BP2 downregulates NT5DC2, which suppresses cell proliferation, and induces cell cycle arrest and apoptosis in diffuse large B‑cell lymphoma cells by regulating the p53 signaling pathway

Targeting TFAP2C/PDCD6 Pathway by lncRNA PP7080 Expedites Tumorigenesis and Contributes to an Immunosuppressive Tumor Microenvironment in Non‐Small Cell Lung Cancer

NT5DC2 Promotes Tumorigenicity of Glioma Stem-like Cells by Upregulating Fyn.

LncRNA TBX5-AS1 Regulates the Tumor Progression Through the PI3K/AKT Pathway in Non-Small Cell Lung Cancer

PRC1 Promotes Cell Proliferation and Cell Cycle Progression by Regulating P21/p27-Prb Family Molecules and FAK-paxillin Pathway in Non-Small Cell Lung Cancer.

ZNF671 Inhibits the Proliferation and Metastasis of NSCLC via the Wnt/β-Catenin Pathway

Circ_0092012 knockdown restrains non-small cell lung cancer progression by inhibiting cell malignant phenotype and immune escape through microRNA-635/programmed death ligand 1 axis

Methylated+58cpg Site Decreases Dcn Mrna Expression And Enhances Tgf-Beta/Smad Signaling In Nsclc Cells With High Metastatic Potential

ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation

IGF2BP3/CTCF Axis–Dependent NT5DC2 Promotes M2 Macrophage Polarization to Enhance the Malignant Progression of Lung Squamous Cell Carcinomas

Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1

GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSP1/AhR/ARNT signaling axis and extracellular exosome secretion

KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway